Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash & Current Investments (2016 - 2025)

UroGen Pharma (URGN) has disclosed Cash & Current Investments for 10 consecutive years, with $112.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments fell 35.23% year-over-year to $112.1 million, compared with a TTM value of $112.1 million through Dec 2025, down 35.23%, and an annual FY2025 reading of $112.1 million, down 35.23% over the prior year.
  • Cash & Current Investments was $112.1 million for Q4 2025 at UroGen Pharma, up from $91.4 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $241.1 million in Q2 2024 and bottomed at $29.5 million in Q3 2022.
  • Average Cash & Current Investments over 5 years is $104.1 million, with a median of $97.9 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments plummeted 72.62% in 2023, then skyrocketed 409.67% in 2024.
  • Year by year, Cash & Current Investments stood at $45.6 million in 2021, then skyrocketed by 119.29% to $100.0 million in 2022, then dropped by 4.14% to $95.8 million in 2023, then surged by 80.61% to $173.1 million in 2024, then tumbled by 35.23% to $112.1 million in 2025.
  • Business Quant data shows Cash & Current Investments for URGN at $112.1 million in Q4 2025, $91.4 million in Q3 2025, and $157.0 million in Q2 2025.